Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
By Rob Curran
Zoetis Inc. posted an increase in first-quarter profit and revenue as demand for pet medicine remained strong.
The animal-medicine company, spun off by Pfizer Inc. in 2013, said earnings rose to $595 million, or $1.26 a share, from $559 million, or $1.18 a share, a year earlier.
Excluding certain items, the company posted adjusted earnings of $1.32 a share.
Foreign-exchange fluctuations weighed on earnings, Zoetis said.
Revenue rose to $1.99 billion from $1.87 billion in the prior-year period.
Sales of companion animal products increased 18%, driven by growth across the company’s parasiticide portfolio, primarily from sales of Simparica Trio, Zoetis said.
Write to Rob Curran at rob.curran@wsj.com
